Tobira Therapeutics Inc. (NASDAQ:TBRA) shares traded down 3.7% on Tuesday . The company traded as low as $4.85 and last traded at $4.88, with a volume of 525,564 shares changing hands. The stock had previously closed at $5.07.

A number of research analysts have weighed in on the stock. Leerink Swann reaffirmed a “buy” rating on shares of Tobira Therapeutics in a research report on Monday, May 2nd. HC Wainwright reiterated a “buy” rating on shares of Tobira Therapeutics in a research note on Wednesday, May 4th. Zacks Investment Research upgraded shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Wednesday, July 13th. Finally, Cowen and Company reiterated a “buy” rating on shares of Tobira Therapeutics in a research note on Tuesday, May 10th. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $16.75.

The stock has a 50 day moving average price of $7.97 and a 200 day moving average price of $8.34. The company’s market capitalization is $86.95 million.

Tobira Therapeutics (NASDAQ:TBRA) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.08. The firm earned $1.06 million during the quarter. Equities research analysts expect that Tobira Therapeutics Inc. will post ($2.65) EPS for the current year.

In other news, major shareholder A/S Novo sold 187,500 shares of the company’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $10.37, for a total value of $1,944,375.00. Following the transaction, the insider now owns 2,093,905 shares in the company, valued at approximately $21,713,794.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP purchased a new stake in shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned 0.57% of Tobira Therapeutics at the end of the most recent reporting period.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.